Name

Acadia Pharmaceuticals Inc.

Legal name

Acadia Pharmaceuticals Inc.

Website

https://acadia-pharm.com

Company type

Public

Founded year

1993

Operating status

Operating

Headcount range

1,001–5,000 employees

Ownership category

akta.pro rank

Product category

Neurology Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)

akta.pro secondary industry

Rare Neurology & Neurodegenerative Disorder Therapies (HLAIAIAD)

Keywords

• Central nervous system drugs
• Rare disease therapeutics
• Neurological disorder therapies
• Parkinson's disease treatments
• Biopharmaceutical products

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Marketing or Sales, Personnel, Operations, Others

Revenue model

1. Pharmaceutical Product Sales: Acadia generates revenue through the sale of prescription pharmaceutical products, primarily NUPLAZID for Parkinson's Disease Psychosis and DAYBUE for Rett syndrome. Revenue is generated through traditional pharmaceutical distribution channels including specialty pharmacies and direct hospital sales. The company reported Q4 2025 net income of $274 million ($1.60 per diluted share) compared to $144 million in Q4 2024, including a $250 million non-cash income tax benefit related to deferred tax assets.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Acadia Pharmaceuticals develops and commercializes FDA-approved small molecule drugs for central nervous system (CNS) disorders and rare neurological diseases. The company markets two commercial brands — NUPLAZID (pimavanserin) for Parkinson's Disease Psychosis and DAYBUE (trofinetide) for Rett syndrome — and is developing a pipeline that includes remlifanserin for Alzheimer's disease psychosis, ACP-211 for depression, ACP-711 for essential tremor, and GPR88 agonists.

Product overview

Acadia Pharmaceuticals is a biopharmaceutical company focused on neurological disorders and rare diseases. The company operates two FDA-approved commercial brands: NUPLAZID (pimavanserin) for Parkinson's Disease Psychosis and DAYBUE (trofinetide) for Rett syndrome. DAYBUE STIX is a new powder formulation of trofinetide launched in 2026. The pipeline includes remlifanserin in Phase 2 for Alzheimer's disease psychosis, ACP-211 for depression, ACP-711 for essential tremor, and GPR88 agonists in preclinical research. Combined net sales projections for NUPLAZID and DAYBUE reach approximately $1.7 billion by 2028.

Differentiator

Problem solved

Functional benefit

Brands

• NUPLAZID: FDA-approved treatment for Parkinson's Disease Psychosis
• DAYBUE
• DAYBUE STIX

Products and services

• NUPLAZID® (pimavanserin)

Quantifiable outcome

• Q1 2026 revenue of $268M, up 11% year-over-year
• +4 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core and minor.

• Michael J. Fox Foundation for Parkinson's ResearchcoreGTM or Marketing Partner · 24 February 2026Acadia Pharmaceuticals is a premier sponsor of the Michael J. Fox Foundation's national event series 'Parkinson's IQ + You,' which has visited 23 cities since 2019. The event educates and empowers people living with Parkinson's disease and their families through interactive panels, research discussions, and a partner expo featuring local and national Parkinson's organizations. The March 2026 event is scheduled in Henderson, Nevada.
• Stoke TherapeuticsminorStrategic or Co-development Partner · 5 November 2025Stoke Therapeutics recognized $10.6 million in revenue from contractual partnerships with Acadia Pharmaceuticals and Biogen. This partnership relates to Stoke's development of genetics-based medicines for severe diseases including Dravet syndrome, with zorevunersen in Phase 3 trials under Breakthrough Therapy Designation. The partnership involves Acadia as a contractual partner contributing to Stoke's development efforts.

Scale indicators15 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Intra-Cellular Therapies: Specialty CNS pharmaceutical company focused on neuropsychiatric disorders (CAPLYTA for schizophrenia/bipolar depression). Direct competitor in CNS specialty pharma targeting similar physician channels (psychiatrists/neurologists) with a single-asset commercial focus analogous to Acadia's NUPLAZID/DAYBUE model.
• Axsome Therapeutics: CNS-focused commercial-stage biopharma with FDA-approved products (AUVELITY for depression, SYMBRAVO for migraine). Comparable to Acadia as a mid-cap CNS specialty company driving revenue growth through focused sales-force deployment in under-met neurological/psychiatric indications.
• Supernus Pharmaceuticals: Specialty pharma focused on CNS disorders including Parkinson's disease (QELBREE, APOKYN). Directly comparable business model of commercializing specialty CNS products through focused field forces targeting neurologists and movement disorder specialists.
• Corcept Therapeutics: Specialty pharma commercializing KORLYM (mifepristone) for Cushing's syndrome with a pipeline in neurological/psychiatric indications. Comparable to Acadia as a small/mid-cap CNS-focused commercial-stage company with concentrated product revenue and selective R&D investment.
• Marinus Pharmaceuticals: Specialty pharma commercializing ZTALMY (ganaxolone) for rare neurological disorders including CDKL5 deficiency disorder. Closely comparable to Acadia in rare/ultra-rare neurological disease focus, small commercial footprint, and orphan disease commercialization.
• Harmony Biosciences: Specialty pharma commercializing WAKIX for narcolepsy with pipeline assets in rare neurological disorders. Comparable to Acadia in mid-cap CNS specialty pharma with focused neurology sales channels and rare disease commercial expertise.

Emerging players

• Sage Therapeutics (now part of Biogen): Was a CNS specialty biopharma commercializing ZURZUVAE (zuranolone) for postpartum depression; acquired by Biogen in 2025. Highly relevant historical peer to Acadia as a CNS-focused innovator with first-in-class approvals in neuropsychiatric indications.
• BioXcel Therapeutics: Clinical-stage biopharma applying AI to neuroinflammation and neuropsychiatry, with IGALMI approved for agitation in schizophrenia/bipolar. Comparable emerging CNS specialty player with a smaller commercial footprint than Acadia but overlapping neurologist/psychiatrist channels.

Broad incumbents

• Biogen: Large biopharma with broad CNS/neurology portfolio (multiple sclerosis, SMA, Alzheimer's via LEQEMBI, depression via ZURZUVAE). Broader incumbent overlap with Acadia's CNS focus, particularly relevant as Alzheimer's disease psychosis and rare neurological disease expansion are pursued.
• Eli Lilly: Large-cap pharma with deep CNS/neurology pipeline (KISUNLA for Alzheimer's, migraine therapies). Broad incumbent with overlapping therapeutic areas (Parkinson's, Alzheimer's) where Acadia's specialty products compete for share of voice with HCPs and payers.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks4 records

Key highlights7 records

Customer concentration

• Xx.com/acadiapharma
• Facebookfacebook.com/155195424515786

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds14 records

Investors18 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Acadia Pharmaceuticals Inc.